Imugene (ASX:IMU) has announced that a bile tract cancer patient in its Phase 1 MAST trial remains a complete response, now surpassing more than two years in remission. 

Australia’s biotechnology industry has gathered in record numbers at the annual AusBiotech conference, held in Melbourne this week.

AusBiotech and the Korea Health Industry Development Institute (KHIDI) have signed a memorandum of understanding establishing a framework for collaboration and cooperation to support each country's growing biotechnology industries.

AusBiotech and Life Sciences Queensland, the leading voice for Queensland’s biotechnology and health innovation sector, have signed a memorandum of understanding to deepen collaboration and advance Australia’s life sciences industry.

AusBiotech and BioMelbourne Network, Victoria’s leading industry association for organisations engaged in biotechnology, medical technology, and health innovation, have signed a memorandum of understanding to promote stronger collaboration.

Amplia Therapeutics (ASX:ATX) is undertaking a placement, director placement and entitlement offer to raise up to $13 million, with interim data from the ACCENT trial supporting its continuation.

"Published preclinical results show the potential immunogenic advantages of this antigen candidate as the basis for an RSV vaccine to provide robust and durable protection,” said Vaxxas CEO David Hoey.

"AusBioInvest is just one way that AusBiotech continues to ensure our investment programmes are designed to the evolving needs of our members at all stages of capital raising, with a laser focus on creating meaningful connections," said AusBiotech CEO Rebekah Cassidy.

Actinogen Medical (ASX:ACW) has announced the appointment of Andrew Udell, a US-based executive, as its chief commercial officer, reporting to CEO Dr Steven Gourlay.

Melbourne-based exteRNA has completed an $11 million seed funding round to support the company's development of therapies targeting a unique aspect of RNA processing.

EMVision Medical Devices (ASX:EMV) has advised that it has received insights and guidance from the US FDA on its planned validation trial to support the emu de novo regulatory clearance pathway.

Kevin Richardson, CEO of Telix Precision Medicine, said, “Telix believes that the FDA approval of Pixclara will drive a step-change for brain cancer imaging in the US and bring it into line with a more advanced standard of care currently used in other markets."

The AusBiotech 2024 Conference, designed by industry for industry, is set to deliver its largest programme yet in the organisation's 38-year history over an exciting four-day programme. 

Australian-Singaporean regenerative medicine company Osteopore (ASX:OSX) has signed an exclusive five-year distribution agreement with Medsite Equipamentos e Produtos Para Saude.

Percheron Therapeutics (ASX:PER) will undertake a share purchase plan for eligible existing shareholders to allow them to participate in a recently announced institutional placement.

AdAlta (ASX:1AD) has announced an addition to its AdCella leadership team, with Dr Kevin Lynch appointed as consultant chief medical officer.

Clinical-stage biotechnology company PYC Therapeutics (ASX:PYC) has announced that the US FDA has designated one of its assets an orphan drug.